Eli Lilly vs Novo Nordisk: What's the Better GLP-1 Stock to Buy?
Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) are leading drugmakers in the highly lucrative GLP-1 market, where demand is through the roof for weight loss medications. But despite both stocks possessing tremendous growth opportunities, it's been Eli Lilly that's been surging in value over the past year, while Novo's valuation has been declining. Is that pattern likely to continue in the future, or could Novo be the better buy right now, given its more modest valuation ? Image source: Getty Images. Continue reading